

Pyrukynd? □Yes □No

PYRUKYND PRIOR APPROVAL REQUEST

Send completed form to: Service Benefit Plan Prior Approval P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 Attn. Clinical Services Fax: 1-877-378-4727

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

	nation (required)			ider Inform	ation (required)
Date:			Provider Name:		
Patient Name:		Specialty:	NP	NPI:	
Date of Birth:	Sex: Male	Female	Office Phone:	Off	fice Fax:
Street Address:			Office Street Address:	I	
City:	State:	Zip:	City:	State:	Zip:
Patient ID: R	1 1 1	1 1	Physician Signature:	I	_
1	I	PHYSICIAN	COMPLETES		
**Check		mulary to confir	nd (mitapivat) m which medication is part of eted in its entirety for pro	-	efit
Is this request for brand or generic	2 DRrand D	Generic			
is this request for braild or generic	er a Brand a C	Jelleric			
How many tablets will the patient	need for an 84 da	y supply?	tablet(s) per 84 c	days	
 What is the patient's diagnosis Anemia Hemolytic anemia with P Other diagnosis (please specific please specific please) 	yruvate Kinase (P.				
2. Does the prescriber agree to do	ose the patient base	ed on hemoglo	bin levels and transfusior	n requirements?	? □Yes □No
3. Does the prescriber agree to ta	per the Pyrukynd	dose with disc	ontinuing therapy to redu	ce the risk of ac	cute hemolysis? □Yes □No
4. Does the patient have moderate	e to severe hepatic	e impairment (Child-Pugh Class B or C)	? □Yes □N	ío
5. Has the patient been on Pyruky	and continuously f	for the last 4 m	onths, excluding samples	<u>s</u> ? Please select	t answer below:
□ NO – this is INITIATION a. Has the patient's condition			• •	ı in the PKLR g	gene? □Yes □No
b. Does the prescriber agre	e to discontinue tr	eatment with F	Pyrukynd if no clinical be	nefit is observed	ed by 24 weeks? □Yes □No
c. What is the patient's hen	noglobin level?	g/d	L <u>OR</u> □Level unkı	nown	
d. Has the patient had 6 or	more red blood ce	ell (RBC) trans	fusion episodes in the last	t 52 weeks (1 ye	ear)? □Yes □No
☐ YES – this is a PA renewal		-		U 1	* *
a. Has there been an increa					
* <i>If NO</i> , has there been	a reduction in the	e need for red b	blood cell (RBC) transfus	ion since initiat	ang therapy with



PYRUKYND PRIOR APPROVAL REQUEST

Send completed form to: Service Benefit Plan Prior Approval P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 Attn. Clinical Services Fax: 1-877-378-4727

Message:

Attached is a Prior Authorization request form.

For your convenience, there are 3 ways to complete a Prior Authorization request:

Electronically Online (ePA) Results in 2-3 minutes FASTEST AND EASIEST	Now you can get responses to drug Prior Authorization requests securely online. Online submissions may receive instant responses and do not require faxing or phone calls. Requests can be made 24 hours a day, 7 days a week. For more information on electronic prior authorization (ePA) and to register, go to Caremark.com/ePA.
Phone (4-5 minutes for response)	The FEP Clinical Call Center can be reached at (877)-727-3784 between the hours of 7AM-9PM Eastern Time. A live representative will assist with the Prior Authorization, asking for the same information contained on the attached form. Please review the form and have your answers ready for faster service. The process over the phone takes on average between 4 and 5 minutes.
Fax (3-5 days for response)	Fax the attached form to (877)-378-4727. Requests sent via fax will be processed and responded to within 5 business days. The form must be filled out completely, if there is any missing information the Prior Authorization request cannot be processed. Please only fax the completed form once as duplicate submissions may delay processing times.

faster...
easier...
Authorizations in minutes through
Caremark.com/ePA. Sign up today!

better...

CVS/caremark